滕紅剛博士自 2024 年 3 月起擔(dān)任遼寧依生總經(jīng)理，并兼任湖岸生物生產(chǎn)制造管理部負(fù)責(zé)人。滕博士在生物醫(yī)藥領(lǐng)域擁有超過 20 年的豐富經(jīng)驗(yàn)，專注于單克隆抗體、HAV 和 HBV 疫苗、HPV 疫苗、狂犬病疫苗以及 HIV/AIDS DNA 疫苗等項(xiàng)目的研發(fā)與制造。在此之前，他曾擔(dān)任江蘇金迪克生物技術(shù)股份有限公司副總經(jīng)理，全面負(fù)責(zé)公司的生產(chǎn)、研發(fā)工作。2016 年 8 月至 2022 年 3 月，滕博士擔(dān)任遼寧依生副總經(jīng)理；2016 年 8 月至 2018 年 11 月，他同時(shí)擔(dān)任遼寧依生生產(chǎn)及質(zhì)量管理部負(fù)責(zé)人。加入本公司之前，滕博士于 2012 年 1 月至 2015 年 6 月?lián)伍L春衛(wèi)爾賽生物藥業(yè)有限公司生產(chǎn)總監(jiān)，并于 2007 年 6 月至 2009 年 6 月?lián)渭謥喬┥锼帢I(yè)股份有限公司副總經(jīng)理。

滕博士于 1995 年 7 月獲得吉林大學(xué)生物化學(xué)學(xué)士學(xué)位，2006 年 7 月獲得吉林大學(xué)生命科學(xué)學(xué)院生物化學(xué)與分子生物學(xué)專業(yè)博士學(xué)位。

Head of Production and Quality Management

Dr. Honggang Teng has served as general manager and head of production and quality management of Liaoning Yisheng since March 2024. Dr. Teng has over 20 years of R&D and manufacturing experience in monoclonal antibodies, HAV and HBV vaccines, HPV vaccine, rabies vaccine, and HIV/AIDS DNA vaccine programs.

Prior to that, he served as vice president of Jiangsu JDK Biotechnology Company Limited and was responsible for overseeing the company’s manufacturing and research & development functions. From August 2016 to March 2022, he served as vice president of Liaoning Yisheng, concurrently acting as head of production and quality management from August 2016 to November 2018.

Prior to joining us, Dr. Teng served as the production director in Chuangchun Zhuoyi Biological Co., Ltd from January 2012 to June 2015. From June 2007 to June 2009, he served as the general manager assistant and vice general manager in Yatai Bio-Pharmaceuticals Co., Ltd.

Dr. Teng obtained his Ph.D. in Biochemistry and Molecular Biology from the School of Life Sciences, Jilin University, in July 2006, and his Bachelor’s degree in Biochemistry from Jilin University in July 1995.